about
Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in ratsUnfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patientsNeuroprotective effects of aspirin in patients with acute cerebral infarctionFamilial hemiplegic migraine with prolonged global aura: follow-up findings of subtraction ictal SPECT co-registered to MRI (SISCOM)Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment.Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia.Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials.Neuroprotection or increased brain damage mediated by temperature in stroke is time dependent.Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemiaOxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins.Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport.Glutamate excitoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke.Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic reviewThe human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke.Interleukin-10 facilitates the selection of patients for systemic thrombolysis.Hyperthermia in human ischemic and hemorrhagic stroke: similar outcome, different mechanismsAssociation between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke.Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic valuesNeuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental studyHigh blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke.The ARTICO study: identification of patients at high risk of vascular recurrence after a first non-cardioembolic stroke.Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice.Neuroplasticity and cellular therapy in cerebral infarction.Role of inflammatory markers in brain ischemia.Laboratory studies in the investigation of stroke.High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke.Endothelial dysfunction, vascular disease and stroke: the ARTICO study.Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia.In vivo theranostics at the peri-infarct region in cerebral ischemia.Targeting the ischemic penumbra.Clinical practice guidelines in intracerebral haemorrhage.Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type.Oxaloacetate: a novel neuroprotective for acute ischemic stroke.Guidelines for the treatment of acute ischaemic stroke.Influence of temperature on ischemic brain: basic and clinical principles.Stroke in 2012: Major advances in the treatment of stroke.Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis.TNFR1 upregulation mediates tolerance after brain ischemic preconditioning.Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis.
P50
Q28190726-45D02323-0F2D-4D45-A2F7-98A67DE2C1D0Q28193517-C4EE38E4-7155-48C0-A377-A6A6ED344F75Q28195362-5B5C670A-AB86-4F9B-BB7F-0B7308F36AC2Q28273889-AE37A349-B69B-43AB-AC13-CC79B10D7D0BQ30572460-73F44814-F943-4015-87AE-BFD44628990EQ30579549-1DA897F8-8E26-4987-962F-2BD2E710D372Q30752758-305C02CB-8C6B-483F-9F4C-DA57849F934FQ34170175-6409417C-B876-4D94-8C3E-C2F5D36E4FA5Q34280852-26D9A0ED-ED1D-4645-8CF4-16475E8DE6D4Q34311208-9CF4082F-787A-42EC-AF4A-8CA3CE60205EQ34365602-A9662CCC-45FA-415A-B238-1DFF04C4094EQ34390240-9E6F9B7C-D1BD-4BCE-A240-92473C5E1A70Q34406399-DED23418-CD9E-4A01-8413-52F2F133D450Q34455124-37AD2443-611A-4258-A754-A075FF12165DQ34681421-5659B686-88D4-4248-9015-B71A081E537DQ34774865-0D3E5D4D-22AA-4F84-B21A-03A0C9934E1CQ35040910-F382649B-5A93-4B2A-8AB4-F3CCC9DF4986Q35042229-F8F0BCD2-B9E0-48DE-B852-F50822AC256EQ35088188-9CCEDF5C-256A-472B-B6DD-144EB3928169Q35088219-2CD179A5-FD70-4C84-8D56-17641F659241Q35088233-439F9909-2241-49DE-90B2-22AFD0EAFECCQ35205210-EF4DF7C8-C172-4CD4-9875-8A9BFE0B81CAQ35615682-4061C21D-B9C8-4392-8261-19C6C5C8C97EQ36986440-7C89D34C-0EEE-49F1-98B7-1A33D9405C17Q37152710-E137A23F-8D2A-4A69-9E12-CCDA71E43CD6Q37269843-69FB7D2E-2EE7-45FD-91D6-F67FA29C223DQ37324392-A372D62F-5CED-4B47-B171-78B29DB37A26Q37431225-2E3D30BB-AB55-4520-949D-13BAC71E92FDQ37431238-7FE12C7C-27E6-4941-BD53-2EE59CEF0FD3Q37435231-437C67D7-0F8E-4943-B419-BBCD88E97E96Q37821638-F31C9B55-6877-48FE-B7BC-1D95A27AA9E7Q37875439-B7E39FF7-CD7D-469C-867D-F5E167923B0AQ37936617-0AECF6BF-6BD4-43B7-82CF-903C46173A70Q37956426-7F50800F-EC3D-4CCC-B839-DFAB977E3C31Q37966157-04A358EF-706D-41C9-B485-A2C2569F8FAAQ37987664-4A2C57F3-7745-401A-86BA-02C97FBFCC3CQ38072302-B23D8381-BA47-407D-A9DE-47116E50C693Q38236852-48416FC3-BB65-4899-889A-EFCA9E9F03AAQ38332109-2CF5A890-ABE2-4F0F-B40B-487125665B25Q39379056-CB191162-2EEE-4F3D-BA4F-2CC0836FE245
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
José Castillo
@ast
José Castillo
@en
José Castillo
@es
José Castillo
@nl
José Castillo
@sl
type
label
José Castillo
@ast
José Castillo
@en
José Castillo
@es
José Castillo
@nl
José Castillo
@sl
altLabel
Jose Castillo
@en
prefLabel
José Castillo
@ast
José Castillo
@en
José Castillo
@es
José Castillo
@nl
José Castillo
@sl
P106
P1153
55766041200
P21
P31
P496
0000-0002-6685-3001